

RECEIVED

13 OCT 2005

#3

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known		
				Application Number	10/530,106	
Sheet		1	of	3	Attorney Docket Number	SLII-P01-003
					Filing Date	April 1, 2005
					First Named Inventor	Rob Hooft Van Huijsduijnen
					Art Unit	N/A
					Examiner Name	Not Yet Assigned

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/S.H./	CA	ANDERSEN et al., 2001, Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. 21:7117-7136			
	CB	BARRY et al., 1993, Introduction of antisense oligonucleotides into cells by permeabilization with streptolysin O, Biotechniques 15:1016-1020			
	CC	BHANDARI et al., 1998, Physical and functional interactions between receptor-like protein-tyrosine phosphatase α and p59 ^{lyn} , J Biol Chem 273:8691-8698			
	CD	BJORGE et al., 2000, Identification of Protein-tyrosine Phosphatase 1B as the Major Tyrosine Phosphatase Activity Capable of Dephosphorylating and Activating c-Src in Several Human Breast Cancer Cell Lines, J. Biol. Chem. 275(52):41439-41446			
	CE	BJORGE et al., 2000, Selected glimpses into the activation and function of Src kinase. Oncogene 19:5620-5635			
	CF	BLASKOVICH and KIM, 2002, Recent discovery and development of protein tyrosine phosphatase inhibitors, Expert Opin. Ther. Patents, 12(6):871-905			
	CG	BOETTIGER et al., 2001, Distinct ligand-binding modes for integrin $\alpha_v\beta_3$ -mediated adhesion to fibronectin versus vitronectin, J. Biol. Chem. 276:31684-31690			
	CH	BOLEN et al., 1992, The Src family of tyrosine protein kinases in hemopoietic signal transduction, FASEB J. 6:3403-3409			
	CI	BRADY-KALNAY and TONKS, 1995, Protein tyrosine phosphatases as adhesion receptors, Curr. Opin. Cell Biol. 7:650-657			
	CJ	BRÜGGEMANN et al., 1992, Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus, Eur. J. Immunol. 21:1323-1326			
/S.H./	CK	CAHIR McFARLAND et al., 1993, Correlation between Src family member regulation by the protein-tyrosine-phosphatase CD45 and transmembrane signaling through the T-cell receptor, Proc. Natl. Acad. Sci. USA 90:1402-1406			

Examiner Signature	/Sheela Huff/	Date Considered	08/21/2007
-----------------------	---------------	--------------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/530,106
		Filing Date	April 1, 2005
		First Named Inventor	Rob Hooft Van Huijsduijnen
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SLII-P01-003
Sheet	2	of	3

/S.H./	CL	CHENG et al., 2001, Attenuation of adhesion-dependent signaling and cell spreading in transformed fibroblasts lacking protein tyrosine phosphatase-1B, J. Biol. Chem. 276:25848-25855	
	CM	COOK and UNGER, 2002, Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity Dev. Cell 2:385-387	
	CN	den HERTOOG et al., 1993, Receptor protein tyrosine phosphatase α activates pp60 ^{csrc} and is involved in neuronal differentiation, Embo J 12:3789-3798	
	CO	den HERTOOG et al., 1999, Receptor protein-tyrosine phosphatase signalling in development, Int. J. Dev. Biol. 43:723-733	
	CP	D'ORO and ASHWELL, 1999, Cutting edge: The CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes, J. Immunol. 162:1879-1883	
	CQ	ESPANEL et al., 2001, Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases, Endocrine 15:19-28	
	CR	FLINT et al., 1997, Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases, Proc. Natl. Acad. Sci. USA 94:1680-1685	
	CS	GALAKTIONOV et al., 1995, CDC25 phosphatases as potential human oncogenes, Science 269:1575-1577	
	CT	GRANTHAM, 1974, Amino acid difference formula to help explain protein evolution, Science, 185:862-864	
	CU	HOOFT van HUIJSDUIJNEN, 1998, Protein tyrosine phosphatases: counting the trees in the forest, Gene 225:1-8	
	CV	HUANG et al., 2001, Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation, Cancer Res. 61:8586-8594	
	CW	HURLEY et al., 1993, Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the <i>lck</i> , <i>fyn</i> , and <i>c-src</i> tyrosine protein kinases, Mol. Cell. Biol. 13:1651-1656	
	CX	KAPILA et al., 2001, Three-dimensional structural analysis of fibronectin heparin-binding domain mutations, J. Cell. Biochem. 36:156-161	
	CY	KIENER and MITTLER, 1989, CD45-protein tyrosine phosphatase cross-linking inhibits T cell receptor CD3-mediated activation in human T cells, J. Immunol. 143:23-28	
	CZ	LEDBETTER et al., 1991, CD45 cross-linking regulates phospholipase C activation and tyrosine phosphorylation of specific substrates in CD3/Ti-stimulated T cells, J. Immunol. 146:1577-1583	
	CA1	LIU et al., 1993, Regulation of c-Src tyrosine kinase activity by the Src SH2 domain, Oncogene 8:1119-1126	
	CB1	MAJETI and WEISS, 2001, Regulatory mechanisms for receptor protein tyrosine phosphatases, Chem. Rev. 101, 2441-2448	
	CC1	MATOZAKI and KASUGA, 1996, Roles of Protein-Tyrosine Phosphatases in Growth Factor Signalling, Cell. Signal. 8(1)13-19	
	CD1	MATOZAKI et al., 1994, Molecular cloning of a human transmembrane-type protein tyrosine phosphatase and its expression in gastrointestinal cancers, J. Biol. Chem. 269:2075-2081	
	CE1	MENDEZ et al., 1997, Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics 15:146-56	
✓	CF1	MENG et al., 2000, Pleiotrophin signals increased tyrosine phosphorylation of β -catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase $\beta\zeta$, Proc. Natl. Acad. Sci. USA 97:2603-2608	
/S.H./	CG1	MÖLLER et al., 1994, Src kinase associates with a member of a distinct subfamily of protein-tyrosine phosphatases containing an ezrin-like domain, Proc. Natl. Acad. Sci. USA 91:7477-7481	

Examiner Signature	/Sheela Huff/	Date Considered	08/21/2007
--------------------	---------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/530,106		
		Filing Date	April 1, 2005		
		First Named Inventor	Rob Hooft Van Huijsduijnen		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	3	of	3	Attorney Docket Number	SLII-P01-003

/S.H./	CH1	NOGUCHI et al., 2001, Inhibition of Cell Growth and Spreading by Stomach Cancer-associated Protein-tyrosine Phosphatase-1 (SAP-1) through Dephosphorylation of p130 ^{cas} , J. Biol. Chem. 276(18):15216-15224
	CI1	PATHAK and YI, 2001, Sodium Slibogluconate Is a Potent Inhibitor of Protein Tyrosine Phosphatases and Augments Cytokine Response in Hemopoietic Cell Lines, J. Immunol. 167:3391-3397
	CJ1	PENG and CARTWRIGHT, 1995, Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association, Oncogene 11:1955-1962
	CK1	RUIVENKAMP et al., 2002, Ptpn1 is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers, Nat. Genet. 31:295-300
	CL1	SAHA et al., 2001, A phosphatase associated with metastasis of colorectal cancer, Science 294:1343-1346
	CM1	SCHMIDT et al., 1996, Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate, Proc. Natl. Acad. Sci. USA 93:3068-3073
	CN1	SEO et al., 1997, Overexpression of SAP-1, a Transmembrane-Type Protein Tyrosine Phosphatase, in Human Colorectal Cancers, Biochem. Biophys. Res. Comm. 231:705-711
	CO1	STANTON et al., 2002, The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. BioChem. J. 364:181-190
	CP1	SUHR et al. 2001, Antisense oligodeoxynucleotide evidence that a unique osteoclastic protein-tyrosine phosphatase is essential for osteoclastic resorption, J. Bone Miner. Res. 16:1795-1803
	CQ1	TAKADA et al., 2002, Induction of Apoptosis by Stomach Cancer-associated Protein-tyrosine Phosphatase-1, J. Biol. Chem. 277(37):34359-34366
	CR1	THOMAS and BRUGGE, 1997, Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13:513-609
	CS1	TOMIZUKA et al., 2000, Double trans-chromosomal mice: maintenance of two individual human chromosome fragments containing Ig heavy and κ loci and expression of fully human antibodies, Proc. Natl. Acad. Sci. USA 97:722-727
	CT1	TUSCHL et al., 1999, Targeted mRNA degradation by double-stranded RNA in vitro, Genes Dev 13:3191-3197
	CU1	UDAYKUMAR and HEWLETT, 1993, A novel method employing UNG to avoid carry-over contamination in RNA-PCR, Nucleic Acids Res. 21:3917-3918
	CV1	WAHL et al., 1983, Improved radioimaging and tumor localization with monoclonal F(ab') ₂ , J. Nucl. Med. 24:316-325
	CW1	WALCHLI et al., 2000, Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on "substrate-trapping" mutants, J. Biol. Chem. 275:9792-9796
	CX1	WIENER et al., 1994, Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas, Am. J. Obstet. Gynecol. 170:1177-1183
	CY1	ZHENG et al., 1992, Cell transformation and activation of pp60 ^{c-src} by overexpression of a protein tyrosine phosphatase, Nature 359:336-339
/S.H./	CZ1	ZONDAG et al., 1995, Homophilic Interactions mediated by receptor tyrosine phosphatases μ and κ. A critical role for the novel extracellular MAM domain, J. Biol. Chem. 270:14247-14250

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Sheela Huff/	Date Considered	08/21/2007
--------------------	---------------	-----------------	------------